Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4591077 | 0.92 | MEN1 (0.39) | MEN1KMT2AHIF1ANPC1RAB9A | |
| SCHEMBL4576219 | 0.91 | HIF1A (0.35) | MEN1KMT2AHIF1AAHRL3MBTL1 | |
| SCHEMBL4906999 | 0.89 | KDM4E (0.45) | MEN1KMT2AHIF1ANPC1RAB9A | |
| SCHEMBL5545343 | 0.88 | MEN1 (0.36) | MEN1KMT2AHIF1ANPC1RAB9A | |
| SCHEMBL4575647 | 0.88 | GRIN2B (0.34) | MEN1KMT2AHIF1AMAPK14 | |
| SCHEMBL4904935 | 0.87 | MEN1 (0.41) | MEN1KMT2AHIF1ANPC1RAB9A | |
| SCHEMBL4591168 | 0.86 | HCRTR1 (0.33) | MEN1KMT2AHIF1A | |
| SCHEMBL4575726 | 0.86 | GRIN2B (0.35) | MEN1KMT2AHIF1A | |
| SCHEMBL5548083 | 0.86 | MEN1 (0.35) | MEN1KMT2AHIF1A | |
| SCHEMBL4576606 | 0.86 | MEN1 (0.37) | MEN1KMT2AHIF1ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | SHIONOGI & CO. LTD (JP) | 2008-09-04 | — | — | US | claimed |
| EP-1910363-A2 | HIV INTEGRASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-04-16 | — | — | EP | claimed |
| WO-2007019098-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | claimed |
| EP-1910363-A2 | HIV INTEGRASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007019098-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | API5, ING2, SAMHD1 | MEN1 4841/4885KMT2A 682/4885HIF1A 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.